Research, Society and Development, v. 15, n. 9, e1915951655, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51655 The anatomy of schizophrenic delusion: An integrative review A anatomia do delírio esquizofrênico: Uma revisão integrativa de literatura Anatomía del delírio esquizofrénico: Una revisión integradora Received: 08/29/2026 | Accepted: 09/03/2026 | Published: 09/05/2026 Giovanna Azevedo Rodrigues ORCID: https://orcid.org/0009-0003-9020-9368 ASMIGO Hospital, Brazil E-mail: giovannagirodrigues@hotmail.com Fernando Martins Castanheira Júnior ORCID: https://orcid.org/0009-0008-7612-9413 ASMIGO Hospital, Brazil E-mail: castanheirasms@gmail.com Marcelo Caixeta ORCID: https://orcid.org/0000-0003-2357-6558 Research Unit – UPC / HC/ UFGO- Clinical Research Unit, Brazil E-mail: cfm11041963@ufg.br Abstract Schizophrenia and psychotic disorders continue to challenge modern psychiatry due to their extreme clinical heterogeneity. This integrative review proposes a dimensional interpretive matrix for understanding the “anatomy of schizophrenic delusion,” grounded in clinical observations and corroborated by a systematic review of recent literature. Using PRISMA methodology and the PICO strategy, we analyzed literature from the past five years on the primary and secondary dimensionality of psychosis, the role of first-rank symptoms, the influence of substance use (cannabis and nicotine) on schizophrenization, intersections with autism spectrum disorder (ASD), and the impact of sleep disturbances on psychotic vulnerability. The proposed model suggests that schizophrenia operates along a continuum in which the central vulnerability resides in the weakness of the secondary ego, the psychic structure responsible for pragmatic mediation with reality, narrative self-coherence, and resilience against affective oscillations. This fragility, whether of neurodevelopmental origin (ASD traits) or acquired through substance use and affective instability (bipolar disorder, BD), facilitates ego evisceration and the emergence of pathognomonic symptoms, particularly Schneider’s first-rank symptoms. Thirty-four studies published between 2017 and 2026 were included in the qualitative synthesis. This integrative review offers an innovative clinical hypothesis that harmonizes classical psychopathology with recent neurobiological findings, with direct therapeutic implications centered on laboralization, sleep hygiene, family expressed emotion reduction, and substance cessation. Keywords: Schizophrenia; Delusion; Autism Spectrum Disorder; Cannabis; Dopamine. Resumo A esquizofrenia e os transtornos psicóticos continuam a desafiar a psiquiatria moderna devido à sua extrema heterogeneidade clínica. Esta revisão integrativa propõe uma matriz interpretativa dimensional para a compreensão da “anatomia do delírio esquizofrênico”, fundamentada em observações clínicas e corroborada por uma revisão sistemática da literatura recente. Utilizando a metodologia PRISMA e a estratégia PICO, analisamos a literatura dos últimos cinco anos sobre a dimensionalidade primária e secundária da psicose, o papel dos sintomas de primeira ordem, a influência do uso de substâncias (cannabis e nicotina) na esquizofrenização, as intersecções com o transtorno do espectro autista (TEA) e o impacto dos distúrbios do sono na vulnerabilidade psicótica. O modelo proposto sugere que a esquizofrenia opera ao longo de um continuum no qual a vulnerabilidade central reside na fragilidade do ego secundário, a estrutura psíquica responsável pela mediação pragmática com a realidade, pela coerência narrativa do eu e pela resiliência contra oscilações afetivas. Essa fragilidade, seja de origem neurodesenvolvimental (traços do TEA) ou adquirida por meio do uso de substâncias e instabilidade afetiva (transtorno bipolar, TB), facilita a destruição do ego e o surgimento de sintomas patognomônicos, particularmente os sintomas de primeira ordem de Schneider. Trinta e quatro estudos publicados entre 2017 e 2026 foram incluídos na síntese qualitativa. Esta revisão integrativa oferece uma hipótese clínica inovadora que harmoniza a psicopatologia clássica com descobertas neurobiológicas recentes, com implicações terapêuticas diretas centradas na laboralização, higiene do sono, redução da expressão emocional familiar e cessação do uso de substâncias. Palavras-chave: Esquizofrenia; Delírio; Transtorno do Espectro Autista; Cannabis; Dopamina. 1 Research, Society and Development, v. 15, n. 9, e1915951655, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51655 Resumen La esquizofrenia y los trastornos psicóticos siguen representando un desafío para la psiquiatría moderna debido a su extrema heterogeneidad clínica. Esta revisión integradora propone una matriz interpretativa dimensional para comprender la "anatomía del delirio esquizofrénico", basada en observaciones clínicas y corroborada por una revisión sistemática de la literatura reciente. Utilizando la metodología PRISMA y la estrategia PICO, analizamos la literatura de los últimos cinco años sobre la dimensionalidad primaria y secundaria de la psicosis, el papel de los síntomas de primer rango, la influencia del consumo de sustancias (cannabis y nicotina) en la esquizofrenización, las intersecciones con el trastorno del espectro autista (TEA) y el impacto de las alteraciones del sueño en la vulnerabilidad psicótica. El modelo propuesto sugiere que la esquizofrenia opera a lo largo de un continuo en el que la vulnerabilidad central reside en la debilidad del yo secundario, la estructura psíquica responsable de la mediación pragmática con la realidad, la autocoherencia narrativa y la resiliencia frente a las oscilaciones afectivas. Esta fragilidad, ya sea de origen neurodesarrollador (rasgos del TEA) o adquirida por el consumo de sustancias y la inestabilidad afectiva (trastorno bipolar, TB), facilita la evisceración del yo y la aparición de síntomas patognomónicos, en particular los síntomas de primer rango de Schneider. Treinta y cuatro estudios publicados entre 2017 y 2026 se incluyeron en la síntesis cualitativa. Esta revisión integradora ofrece una hipótesis clínica innovadora que armoniza la psicopatología clásica con los hallazgos neurobiológicos recientes, con implicaciones terapéuticas directas centradas en la inserción laboral, la higiene del sueño, la reducción de la expresión emocional en la familia y el abandono del consumo de sustancias. Palabras clave: Esquizofrenia; Delirio; Trastorno del Espectro Autista; Cannabis; Dopamina. 1. Introduction Historically, Kraepelin’s dichotomy between dementia praecox and manic-depressive illness has guided psychiatric classification for over a century (Jablensky, 2021). This binary division, while useful as a starting point, generated a diagnostic tradition that tends to treat schizophrenia as a discrete and homogeneous entity, separated by clear boundaries from other mental disorders. However, the validity of rigid diagnostic categories has been widely questioned in recent decades in favor of dimensional approaches, such as the Research Domain Criteria (RDoC) and the Hierarchical Taxonomy of Psychopathology (HiTOP), Sieler et al. (2025), in a study published in Schizophrenia, demonstrated that a dimensional approach to psychosis, identifying cognition, depression, and thought disorder factors in a clinical sample, captures the heterogeneity of psychotic disorders with greater fidelity than traditional diagnostic categories (Sieler et al., 2025). This evidence reinforces what daily clinical practice already suggests: schizophrenic delusion rarely arises in isolation, but rather as the final stage of a schizophrenization process involving multiple interrelated risk factors accumulated over time. Schizophrenia is a disorder with a lifetime prevalence of approximately 0.4%, typically manifesting in late adolescence or early adulthood, and is associated with high functional disability and reduced life expectancy (Leucht et al., 2025). The first psychotic episode is frequently preceded by a long prodromal phase, which can last several years, during which subclinical affective, cognitive, perceptual, and identity disturbances progressively accumulate (Leucht et al., 2025). During this period, aberrant salience, defined as the inappropriate attribution of meaning to neutral stimuli, emerges as a transdiagnostic marker of psychotic vulnerability, present from the earliest stages of the continuum, following the sequence from anomalous selfexperiences and basic symptoms, through attenuated psychotic syndrome, and finally to full-blown psychosis (Marano et al, 2025). Marano et al. (2025) demonstrated that, in youths with an ultra-high risk (UHR) mental state, abnormal salience processing can be identified before the first psychotic episode, configuring a priority target for early intervention. The neurobiology underlying this process involves, in its final common pathway, mesolimbic hyperdopaminergia and dysfunction in associative cortico-striatal circuits. Corlett & Fraser (2025), in a critical review published in the American Journal of Psychiatry, revisited two decades of the aberrant salience hypothesis and demonstrated that the primary defect in psychosis does not simply reside in excess dopamine in the ventral striatum, but in the failure of belief formation and updating circuits under uncertainty, preferentially located in the head of the caudate, the associative striatum, and the dorsolateral prefrontal cortex. This neurobiological refinement is of paramount importance: it explains why Schneider’s first-rank symptoms (FRS), including thought insertion, withdrawal, broadcasting, and somatic passivity, represent not merely delusions of content, but a structural 2 Research, Society and Development, v. 15, n. 9, e1915951655, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51655 failure in the attribution of agency and ownership over one’s own mental processes. Magrangeas et al. (2022), in a study of 9,323 patients in routine clinical practice, confirmed that somatic passivity and thought interference are independent predictors of shortand medium-term negative outcomes, with adjusted ORs between 1.24 and 1.61. Concurrently, recent literature has consolidated the role of two environmental catalysts of enormous clinical relevance: autism spectrum disorder (ASD) and psychoactive substance use. Individuals with ASD have a significantly increased risk of developing psychosis, with comorbidity rates between 9% and 34%, and differentiating between autistic and psychotic symptoms remains a major diagnostic challenge (Jutla, Foss-Feig & Veenstra-VanderWeele, 2022). Cannabis use, in turn, amplifies vulnerability to psychosis through the activation of CB1 receptors, GABAergic disinhibition in the ventral tegmental area, and consequent mesolimbic hyperdopaminergia (Tseng & Molla, 2025; Weinstein, 2023). Bello et al. (2026), in a prospective study from the NAPLS-2 consortium, demonstrated that the co-use of cannabis and tobacco increases the risk of conversion to psychosis in high-risk individuals with a hazard ratio of 2.93 (95% CI: 1.23–6.97). These data show that schizophrenization is not a spontaneous process, but a trajectory that can be accelerated, decelerated, or even reversed depending on environmental exposure. The concept of the “Anatomy of Schizophrenic Delusion” proposed in this article does not refer to neuroanatomical structures, but to the psychopathological dissection of delusion formation. It is proposed that the schizophrenic process operates along a dimensional spectrum, ranging from primary forms, strongly anchored in neurodevelopment and genetics, to secondary forms, driven by environmental stressors and substances upon a vulnerable baseline. The common link between these dimensions is the depletion or failure in the consolidation of the “secondary ego”: the psychic structure responsible for pragmatic mediation with reality, for resilience against affective oscillations, and for maintaining the individual’s narrative coherence over time. When this secondary ego collapses, the neurobiological substrate responds with the aberrant attribution of salience that culminates in the evisceration of ego boundaries and the emergence of first-rank symptoms. Delusion, in this sense, is not the beginning of the story, but its final chapter. Understanding the preceding chapters is what allows for intervention before it is written. This integrative review proposes a dimensional interpretive matrix for understanding the “anatomy of schizophrenic delusion,” grounded in clinical observations and corroborated by a systematic review of recent literature. Using PRISMA methodology and the PICO strategy, we analyzed literature from the past five years on the primary and secondary dimensionality of psychosis, the role of first-rank symptoms, the influence of substance use (cannabis and nicotine) on schizophrenization, intersections with autism spectrum disorder (ASD), and the impact of sleep disturbances on psychotic vulnerability. 2. Metodology This integrative review was conducted following the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020), adapted for integrative reviews that synthesize heterogeneous evidence with the aim of building or testing theoretical models. The integrative review design was chosen, rather than a strict systematic review, due to the nature of the research question, which involves integrating findings from distinct study designs (observational studies, clinical trials, systematic reviews, meta-analyses, and neuroimaging studies) around a dimensional clinical hypothesis. This type of review is recognized in methodological literature as the most appropriate for synthesizing knowledge in areas where the heterogeneity of investigated phenomena precludes quantitative meta-analyses (Page et al., 2021). 2.1 Research Question and PICO Strategy The research question guiding this review was: What evidence from recent literature supports a dimensional model of schizophrenia centered on the failure of the secondary ego as a common mechanism for both primary and secondary forms of schizophrenic delusion? The structured formulation followed the PICO strategy, detailed in Table 1. 3 Research, Society and Development, v. 15, n. 9, e1915951655, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51655 2.2 Data Sources and Search Strategy The literature search was conducted in the PubMed/MEDLINE, Scopus, PsycINFO, and Google Scholar databases, with a cutoff date of June 2026. Priority was given to articles published in the last five years (2021–2026), although fundamental classic references were retained when relevant for the historical conceptual framework. The search strategy utilized controlled vocabulary (MeSH) and free terms combined with Boolean operators, as described in Table 1. Table 1 — Search Strategy by Thematic Domain. Source: Authors. Table 1 — Search Strategy by Thematic Domain: This table outlines the specific MeSH and free-text search terms utilized across various thematic domains related to psychosis and schizophrenia research, such as dimensionality, substance use, sleep disturbances, and aberrant salience. 2.3 Eligibility Criteria Inclusion criteria: (1) original articles, systematic reviews, meta-analyses, narrative reviews, and umbrella reviews; (2) published between 2021 and 2026, with the exception of seminal references prior to this period; (3) in English or Portuguese; (4) addressing at least one of the thematic domains listed in the search strategy; (5) with empirical data or synthesis of evidence of verifiable quality. Exclusion criteria: (1) articles dealing exclusively with pharmacological treatment without addressing psychopathological or neurobiological mechanisms; (2) isolated case reports without an associated literature review; (3) opinion pieces without empirical basis; (4) animal studies without explicit clinical translation to humans; (5) publications without peer review. 2.4 Study Selection and Data Extraction Study selection was performed in two stages by two independent reviewers (G.A.R. and F.M.C.J.). In the first stage, titles and abstracts were evaluated to verify preliminary eligibility. In the second stage, the full texts of the pre-selected articles were read in their entirety. Disagreements between reviewers were resolved by consensus or, when necessary, by consulting the 4 Research, Society and Development, v. 15, n. 9, e1915951655, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51655 supervisor (M.C.). Data extracted from each study included: author(s), publication year, journal, country, study design, sample size, studied population, main findings related to the domains of interest, and methodological quality assessment. 2.5 Methodological Quality Assessment The methodological quality of the included studies was assessed according to the study design. For systematic reviews and meta-analyses, the AMSTAR-2 (A Measurement Tool to Assess Systematic Reviews) instrument was used. For observational studies, the Newcastle-Ottawa Scale (NOS) was utilized. For neuroimaging studies, criteria from the Cochrane Risk of Bias Tool adapted for non-randomized studies were applied. Studies with critically low methodological quality (AMSTAR-2 level 4 or NOS < 4 stars) were included only when they represented the sole available evidence for a specific domain, being explicitly flagged as such in the discussion. 2.6 Data Synthesis and PRISMA Flow Diagram Given the integrative nature of the review and the heterogeneity of the included designs, a structured narrative synthesis was chosen over quantitative meta-analysis. The synthesis was organized around the five thematic axes identified a priori by the PICO strategy, with progressive integration of findings into an interpretive matrix. The study selection process is described in the PRISMA flow diagram (Figure 2), which details the number of records identified, screened, excluded, and included at each stage. Figure 1 - PRISMA 2020 Flow Diagram — Source: 06 july, 2026. Source: Authors. 5 Research, Society and Development, v. 15, n. 9, e1915951655, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51655 Figure 1. PRISMA 2020 flow diagram illustrating the study selection process. A total of 870 records were identified across four databases (PubMed/MEDLINE, Scopus, PsycINFO, Google Scholar) and additional sources. After removal of duplicates (n = 172), 698 records were screened by title and abstract. Following full-text assessment of 57 articles, 23 were excluded for reasons detailed in the diagram. A total of 34 studies were included in the qualitative synthesis. Adapted from: Page MJ et al. PRISMA 2020 explanation and elaboration. BMJ. 2021;372:n160. A study employing a quantitative approach was conducted regarding the 870 initial studies—which were narrowed down to 34 selected articles to form the corpus of the present study—and a qualitative approach regarding the discussions (Gil, 2026; Risemberg et al., 2026; Pereira et al., 2018). 3. Results and Discussion The 34 selected articles were those by the authors: Ahrens et al. (2025); Azargoonjahromi & Bahrampour (2025); Bello et al. (2026); Chu et al. (2023); Corlett & Fraser (2025); Fusar-Poli et al. (2013); Geoffroy et al. (2025); Guerrera et al. (2024); Henriksen, Nordgaard & Jansson (2017); Howes & Kapur (2009); Jablensky (2021); Jeong & Son (2026); Kapur (2003); Keegan, Brown & Gaynor (2025); Krystal et al. (2003); Leucht et al. (2025); López-Silva et al. (2024); Magrangeas et al. (2022); Marano et al. (2025); Mu et al. (2024); Murrie et al. (2020); Nordgaard & Parnas (2023); Nusslock, Mittal & Alloy (2025); O’Brien et al. (2026); Ribolsi et al. (2022); Sass & Parnas (2003); Sieler, Kircher & Nenadić (2025); Skumlien, Langley & Sahakian (2023); Stein & Kircher (2025); Tseng & Molla (2025); Uhlhaas & Singer (2010); Wang et al. (2022); Weinstein (2023); Yazihan (2025) The analysis of the selected literature allowed for structuring the interpretive matrix of the Anatomy of Schizophrenic Delusion into five fundamental axes, which directly inform the proposed clinical hypothesis. Figure 2 visually synthesizes the proposed dimensional model, illustrating how vulnerabilities converge towards the failure of the secondary ego and the emergence of delusion. Figure 2 — Dimensional Interpretive Matrix of Schizophrenic Delusion. Source: Authors. Figure 2. Dimensional interpretive matrix of the Anatomy of Schizophrenic Delusion. The model illustrates how three primary vulnerability pathways — neurodevelopmental (ASD traits), affective (BD), and toxic (cannabis/nicotine co-use) — 6 Research, Society and Development, v. 15, n. 9, e1915951655, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51655 converge on the failure of the secondary ego, culminating in the emergence of Schneider’s first-rank symptoms. Laboralization is represented as the central protective factor capable of reinforcing the secondary ego across all three pathways. 3.1 The dimensionality of schizophrenia: primary vs. secondary Recent literature progressively moves away from watertight diagnostic categories towards dimensional and transdiagnostic models that more faithfully capture the clinical heterogeneity of psychotic disorders. Stein & Kircher (2025), in a qualitative review published in the Journal of Affective Disorders that synthesized genetic, neuroimaging, and psychopathological findings in major depression, bipolar disorder (BD), and schizophrenia, demonstrated that genetic, cognitive, and neuroimaging overlaps among these three disorders challenge traditional categorical distinctions and support the hypothesis of a continuum of major psychoses (Stein & Kircher, 2025). The authors argue that dimensional approaches, such as the Research Domain Criteria (RDoC), the Hierarchical Taxonomy of Psychopathology (HiTOP), and clinical staging, offer superior conceptual frameworks for understanding these disorders along a spectrum, with direct implications for personalized diagnostic and therapeutic strategies (Stein & Kircher, 2025). Sieler et al. (2025) empirically confirmed this perspective by identifying latent dimensional factors that cross psychotic disorders, including cognition, depression/negative symptoms, and thought disorder. The model proposed here aligns with this view, suggesting that there is no rigid categorical cutoff between primary and secondary schizophrenia, but rather a continuum where the central vulnerability resides in the strength or weakness of the secondary ego. Understanding the dimensionality of schizophrenia requires a developmental perspective that considers psychosis as the possible outcome of vulnerabilities accumulating across different stages of brain maturation. In their 2026 narrative review, O'Brien et al. (2026) synthesized findings from genetics, developmental neuroscience, early-life adversity, and resilience research, emphasizing that susceptibility to psychotic disorders may originate before birth and subsequently be shaped by the interaction between biological predisposition and environmental experience (O’Brien et al., 2026). Rather than representing a single period of vulnerability, neurodevelopment appears to involve successive windows during which environmental influences may have particularly important consequences. The prenatal period is especially relevant for the generation and initial organization of cortical networks, whereas adolescence is characterized by extensive remodeling of previously established neural systems, including changes in synaptic connectivity, myelination, and circuits involved in executive functioning, reward, and social cognition (O’Brien et al., 2026). Within the proposed interpretive model, adolescence therefore represents a particularly relevant developmental context in which ASD-related traits, affective instability associated with BD, and exposure to psychoactive substances may converge. Their interaction is hypothesized to interfere with the progressive consolidation of what is here termed the secondary ego, increasing susceptibility to maladaptive patterns of adaptation. This formulation extends the developmental framework proposed by O'Brien et al. rather than being directly derived from their review (O’Brien et al., 2026). In primary schizophrenia, a pre-existing neurodevelopmental vulnerability may be clinically expressed through characteristics such as impaired social cognition, behavioral rigidity, and difficulties in interpreting emotional information. Within the present model, these features may interact during adolescence with affective dysregulation and substance exposure, a developmental period in which substantial biological and psychosocial changes occur. Importantly, O'Brien et al. report that only a proportion of individuals considered at clinical high risk (CHR) for psychosis subsequently develop a threshold psychotic disorder, with transition estimates generally ranging from 20% to 30%; moreover, some individuals experience complete remission of psychotic symptoms (O’Brien et al., 2026). These findings support a fundamental distinction between vulnerability 7 Research, Society and Development, v. 15, n. 9, e1915951655, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51655 and deterministic progression: the presence of risk factors does not inevitably lead to psychosis, and developmental trajectories may be modified by protective or adverse influences. This principle is incorporated into the proposed model through the concept of laboralization. Laboralization is understood here as a potentially protective process. It provides structure, organization, and adaptive engagement during development. The proposed model distinguishes between primary and secondary forms of schizophrenization. Individuals with fewer baseline ASD-related traits fall into the secondary category. This model characterizes them phenomenologically as naive, jovial, or pragmatically immature. Such individuals are conceptualized as more dependent on environmental determinants of clinical trajectory. Conversely, insufficient occupational structuring removes this protective effect. In such cases, psychoactive substance exposure and impulsive hedonism are hypothesized to play a more prominent role. Both factors are thought to contribute to the progressive schizophrenization process (Murrie et al., 2020). At both poles of the spectrum, pathogenesis converges on the failure of the “secondary ego” reserve. The secondary ego, a central concept of the proposed interpretive matrix, can be understood as the psychic structure responsible for pragmatic mediation with reality, for maintaining the narrative cohesion of the self, and for resilience against affective oscillations and environmental intrusions. The weaker the secondary ego. Whether rooted in neurodevelopmental constitution (ASD), chronic affective destabilization (BD), or toxic erosion by cannabis and nicotine, the more the individual is dominated by external stimuli and internal oscillations, progressively losing the capacity to distinguish what is their own from what is alien, what is perception from what is projection, and what is memory from what is delusion. Table 2 — Primary vs. Secondary Schizophrenia. Legend: BD = Bipolar Disorder. This table provides a comparative analysis of Primary and Secondary Schizophrenia, highlighting key differences in their neurodevelopmental basis, external catalysts, and clinical symptoms, while also suggesting a proposed continuum between the two conditions. Source: Authors. 3.2 The intersection between ASD and psychosis in delusion formation The overlap between autism spectrum disorder (ASD) and psychosis is one of the most intriguing findings in contemporary psychiatry and, at the same time, one of the most underestimated in clinical practice. Recent meta-analyses indicate that adults with ASD have rates of psychotic disorders up to ten times higher than the general population, with psychosis prevalence ranging between 9% and 34% depending on the methodology used (Jutla, Foss-Feig & Veenstra-VanderWeele, 8 Research, Society and Development, v. 15, n. 9, e1915951655, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51655 2022). Gesi et al. (2024), in a review published in the Journal of Psychiatric Research, highlight that autistic symptoms frequently cause “diagnostic overshadowing”: the tendency to attribute all unusual behaviors to the preexisting ASD diagnosis, neglecting the emergence of a true psychosis that requires specific treatment (Jutla, Foss-Feig & Veenstra-VanderWeele, 2022).. This phenomenon has serious clinical consequences, as it delays the initiation of antipsychotic treatment at a phase when early intervention is determinant for long-term prognosis. A deeper understanding of this overlap requires a return to conceptual origins. Jeong & Son (2026), in a historical and phenomenological review published in the Journal of the Korean Academy of Child and Adolescent Psychiatry, demonstrated that the very concept of “autism” has dual and divergent roots in the history of psychiatry: Bleuler’s “Autismus” (1911) designated the active withdrawal from reality and the construction of a fantasy internal world as a cardinal symptom of schizophrenia, while Kanner’s “infantile autism” (1943) described an innate deficit in the formation of affective bonds (Jeong & Son, 2026). This conceptual divergence, which persisted for decades, obscured the profound neurobiological and phenomenological similarities between the two disorders. The phenomenological analysis by Jeong and Son (2026) revealed that, while patients with schizophrenia exhibit an ipseity disturbance characterized by instability of the minimal self, hyperreflexivity, and dissolution of ego boundaries, while patients with ASD present a preserved minimal self, but with a profound deficit in intersubjective attunement (Jeong & Son, 2026). This distinction is clinically fundamental: in ASD, the secondary ego is not structurally dissolved, but chronically under-exercised due to a lack of adequate social feedback, making it vulnerable to collapse when subjected to intense affective pressure. This neurodevelopmental perspective allows for a precise dissection of how schizophrenic delusion forms. Take the clinical example of the “strange mother delusion.” Individuals with ASD traits have intrinsic difficulty reading emotional and social cues, a consequence of impaired theory of mind and dysfunction in mirror neurons that support automatic affective empathy. When placed in a high expressed emotion environment, such as a dependent relationship with an overwhelmed, critical, or emotionally unpredictable maternal figure, the inability to decode maternal affect generates growing existential anguish. The patient fills this cognitive gap with obsessive ideation which, combined with the poverty of pragmatic repertoire and cognitive rigidity characteristic of ASD, crystallizes into a projective elucubration. What classical phenomenology summarily classifies as persecutory delusion is, in fact, the collapse of social cognition under affective pressure: not a primary break with reality, but a desperate attempt to make sense of a relational world that remains opaque. Ribolsi et al. (2022) corroborate this observation, demonstrating that psychosis in individuals with ASD frequently emerges in contexts of relational overload and that interventions focused on reducing family expressed emotion produce faster symptomatic remission (Canitano & Pallagrosi, 2017). Keegan et al. (2025), in a systematic review published in Early Intervention in Psychiatry that analyzed 15 studies with patients in first-episode psychosis, confirmed that high family expressed emotion, characterized by critical comments, hostility, and emotional over-involvement, is consistently associated with greater symptom severity, poorer social functioning, and shorter time to relapse (Keegan, Brown & Gayno, 2025). Notably, the authors identified that family burden and emotional over-involvement are independent predictors of negative outcomes, even after controlling for patient clinical variables. This finding has direct implications for the anatomy of delusion in ASD: maternal emotional over-involvement, which frequently emerges as an adaptive response to the dependence of the child with ASD, paradoxically creates the high expressed emotion environment that precipitates psychotic decompensation. The following table synthesizes the main differences and overlaps between ASD and schizophrenia that are relevant for understanding the anatomy of delusion: 9 Research, Society and Development, v. 15, n. 9, e1915951655, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51655 Table 3 — ASD and Schizophrenia. Legend: This finding suggests that psychosis in ASD is not merely a neurobiological epiphenomenon, but a maladaptive adaptive response to a social environment incompatible with the patient’s cognitive profile. The most effective therapeutic intervention, therefore, is not exclusively pharmacological: family psychoeducation, reduction of expressed emotion, and social cognition training represent first-line therapeutic pillars in this population. Source: Authors. 3.3 The catalytic role of substances: cannabis, nicotine, and amotivational syndrome The use of psychoactive substances acts as one of the most potent vectors of schizophrenization, especially in secondary forms. Understanding this role requires, however, moving beyond epidemiology and delving into the neurobiological mechanisms by which cannabis and nicotine progressively compromise the integrity of the secondary ego. 3.3.1 The endocannabinoid system and the final common pathway to psychosis The endocannabinoid system (ECS) is one of the most abundant neurotransmission systems in the central nervous system, composed of G protein-coupled receptors, primarily cannabinoid receptor type 1 (CB1R) and type 2 (CB2R), and endogenous ligands (endocannabinoids). CB1Rs are highly expressed in brain areas critical for cognition, memory, reward, and emotional regulation, including the prefrontal cortex, hippocampus, amygdala, and basal ganglia. Δ⁹-tetrahydrocannabinol (THC), the main psychoactive compound in cannabis, acts as a partial agonist at CB1R. Unlike endogenous endocannabinoids, which function as retrograde messengers released by the postsynaptic neuron to modulate neurotransmitter release at the presynaptic terminal, THC exerts a tonic, persistent, and unregulated activation of CB1R, subverting the physiological homeostatic mechanism. Tseng & Molla (2025), in an expert review published in Molecular Psychiatry, demonstrated that CB1R expression peaks in early adolescence and progressively declines into young adulthood, both in humans and animal models (Tseng & Molla, 2025). This developmental pattern explains the specific vulnerability window of adolescence: exposure to THC during this sensitive period encounters an endocannabinoid system undergoing major reorganization, with high CB1R density and intense synaptic plasticity, making the neurobiological consequences potentially permanent. The mechanism by which THC induces psychosis involves a cascade of events converging on the mesolimbic dopaminergic pathway. At the synaptic level, CB1R is predominantly located on presynaptic terminals of GABAergic interneurons. GABA, the main inhibitory neurotransmitter in the brain, exerts tonic control over dopaminergic neurons in the ventral tegmental area (VTA). When THC activates CB1Rs on these GABAergic interneurons, it suppresses GABA release, 10 Research, Society and Development, v. 15, n. 9, e1915951655, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51655 resulting in disinhibition of VTA dopaminergic neurons. The result is an unregulated increase in dopamine release in the ventral striatum and prefrontal cortex, mimicking the pattern of striatal hyperdopaminergia described in the dopamine hypothesis of schizophrenia. Concurrently, CB1R activation in cortical astrocytes promotes astrocytic glutamate release, amplifying cortical excitation and contributing to the state of aberrant salience attribution. A high-impact neuroimaging study published in JAMA Psychiatry by Ahrens et al. (2025) provided the most direct evidence to date that cannabis and psychosis converge on the same dopaminergic pathway (Ahrens et al., 2025). Using neuromelanin-sensitive magnetic resonance imaging (NM-MRI), an indirect marker of long-term dopaminergic function in the substantia nigra/VTA (SN/VTA), the authors investigated 61 individuals with and without cannabis use disorder (CUD), with and without a diagnosis of first-episode schizophrenia. The results were remarkable: CUD was associated with elevated NMMRI signal in a specific subregion of the ventral SN/VTA that had previously been identified as a correlate of untreated psychosis severity. More importantly, this association followed a dose-dependent pattern: the greater the burden of CUD symptoms, the higher the NM-MRI signal in the psychosis-related region of interest. This finding suggests that cannabis activates the same dopaminergic pathway that constitutes the final common pathway for the clinical expression of psychotic symptoms, regardless of whether the individual has a formal diagnosis of schizophrenia (Ahrens et al., 2025). A SPECT neuroimaging study published in Frontiers in Psychiatry by Weinstein (2023) complemented this picture by investigating dopamine D₂ receptor availability in the striatum of abstinent cannabis users who had recovered from cannabisinduced psychosis (Weinstein, 2023). The findings indicated that, after four months of abstinence and treatment, D₂ availability in the caudate returned to levels comparable to those of healthy controls, suggesting that cannabis-induced dopaminergic dysregulation is partially reversible. However, a non-significant trend of reduced D₂ availability was observed in the right putamen, possibly related to residual effects of antipsychotic medication, indicating that complete recovery may not be universal (Weinstein, 2023). 3.3.2 Chronic use, CB1R downregulation, and amotivational syndrome Acute and chronic cannabis use exert opposing and complementary effects on the dopaminergic system. While acute THC exposure produces a peak of mesolimbic dopaminergic release, chronic and repeated use leads to adaptive downregulation of CB1Rs, particularly in the striatum and prefrontal cortex. This desensitization reduces the responsiveness of the reward system to natural stimuli, creating a state of anhedonia and avolition that is the neurobiological signature of amotivational syndrome. Amotivational syndrome has been historically debated, with initial studies showing conflicting results. Skumlien et al. (2024), in a comprehensive review published in Current Behavioral Neuroscience Reports, clarified this apparent paradox by precisely distinguishing the acute from the non-acute effects of cannabis on motivation (Skumlien, Langley & Sahakian, 2024). The authors reviewed studies using validated effort-reward behavioral tasks, notably the Effort Expenditure for Reward Task (EEfRT), in which participants choose between low- and high-effort tasks to obtain monetary rewards of different magnitudes. The results were surprising: in the non-acute state (after at least 12 hours of abstinence), three independent studies found that cannabis users chose more high-effort tasks than controls, with medium to large effect sizes (Cohen’s d = 0.54 to ηp² = 0.104). Two other studies found no differences. No non-acute study found lower motivation in cannabis users (Skumlien, Langley & Sahakian, 2024). However, the scenario changes radically during acute intoxication. Wardle et al. (cited in Skumlien et al., 2024) demonstrated that 15 mg of ingested THC reduced the choice of high-effort tasks by 55% compared to placebo in young adult women, with a specific effect on high expected value choices (Skumlien, Langley & Sahakian, 2024). This contrast is fundamental for clinical understanding: the chronic cannabis user is not intrinsically amotivated at baseline, but becomes 11 Research, Society and Development, v. 15, n. 9, e1915951655, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51655 profoundly amotivated during periods of intoxication, which in daily use correspond to most waking hours. The sum of these repeated episodes of acute amotivation, over months and years, produces the clinical picture of amotivational syndrome. More critically, Skumlien et al. (2024) found a consistent association between cannabis use disorder (CUD) and apathy in self-report measures, even in the absence of differences in behavioral tasks (Skumlien, Langley & Sahakian, 2024). This suggests that CUD produces a form of subjective and experiential apathy that is not captured by laboratory effort-reward tasks, but which is clinically relevant and manifests in daily life as reduced initiative, persistence, and social engagement. This distinction between subjective apathy and laboratory task performance is crucial: the secondary ego is not just a behavioral entity, but an experiential and narrative structure that can be eroded even when performance on isolated tasks remains preserved. A fundamental link between cannabis-induced amotivational syndrome and vulnerability to psychosis is reward processing. Nusslock, Mittal, & Alloy (2025), in a review published in the “Annual Review of Clinical Psychology”, proposed a neurodevelopmental framework suggesting that alterations in reward processing may arise through distinct mechanisms in mood disorders and schizophrenia (Nusslock, Mittal, & Alloy, 2025). In bipolar disorder (BD), disturbances in reward-related behavior are primarily associated with abnormal regulation of motivational and hedonic responses, with increased sensitivity to rewarding cues during mania and reduced responsiveness during depressive episodes (Nusslock, Mittal, & Alloy, 2025). Schizophrenia, in contrast, appears to involve a different pattern in which difficulties in evaluating reward information across time and in selectively directing attention toward relevant stimuli may contribute to impaired reward processing, without necessarily implying a primary deficit in motivation or hedonic capacity (Nusslock, Mittal, & Alloy, 2025). This distinction is particularly relevant to the proposed interpretive matrix, as chronic cannabis exposure may alter reward-related cognition through interactions between prefrontal CB1R signaling and striatal dopaminergic pathways, potentially generating a functional state that overlaps with, and may exacerbate, reward-processing abnormalities observed in schizophrenia. In primary schizophrenia, avolition and apathy are recognized as core negative symptoms and determinants of functional outcome. Shao et al. (2024), in a study published in the European Archives of Psychiatry and Clinical Neuroscience, developed a novel effort-based decision-making task in social scenarios (mock job interview) and applied it to 45 patients with schizophrenia and 49 controls (Shao et al., 2024). The results demonstrated that patients with schizophrenia were significantly less likely to choose high-effort tasks with demanding interviewers, especially when the reward was of medium to high value. More importantly, the severity of apathy symptoms correlated directly with the reduction in willingness to exert effort, and patients were especially reluctant to exert effort for jobs requiring greater social engagement (Shao et al., 2024). This finding expands the concept of amotivational syndrome beyond the monetary domain: avolition in schizophrenia is especially pronounced in the social domain, which aligns directly with the difficulty in laboralization observed clinically and with the tendency toward isolation and passivity. In the context of the proposed model, amotivational syndrome represents the neurochemical and experiential erosion of the secondary ego. The individual becomes progressively passive, with a loosening of pragmatic ties to reality, reduced social initiative, and increasing vulnerability to affective oscillations and delusional intrusions. Laboralization, therefore, is not just a generic psychosocial intervention: it is a strategy for restoring prefrontal dopaminergic integrity and the cognitive representation of rewards, directly countering the state of avolition induced by chronic cannabis use and primary schizophrenic processes. 3.3.3 Nicotine, dopaminergic dysregulation, and the self-medication paradox Nicotine occupies a peculiar place in this equation. The prevalence of smoking in patients with schizophrenia is up to 62%, three times higher than in the general population (Bello et al., 2026). This strong association led to the self-medication hypothesis: nicotine, by activating nicotinic acetylcholine receptors (nAChRs), particularly α7 and α4β2 subtypes, increases 12 Research, Society and Development, v. 15, n. 9, e1915951655, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51655 dopamine release in the striatum and prefrontal cortex, which could transiently attenuate negative symptoms and cognitive deficits of schizophrenia. Mu et al. (2024), in a prospective longitudinal study published in Schizophrenia (Nature), investigated the impact of smoking on symptom improvement in 145 medication-naive male patients with first-episode schizophrenia (Mu et al., 2024). After 12 weeks of antipsychotic monotherapy treatment, smokers demonstrated greater improvement in negative symptoms compared to non-smokers, after controlling for confounding variables. This finding corroborates the self-medication hypothesis, but at the same time exposes its trap: nicotine offers short-term symptomatic relief at the cost of progressive, long-term subcortical dopaminergic dysregulation, which perpetuates and aggravates vulnerability to psychosis (Mu et al., 2024). The mechanism by which nicotine contributes to schizophrenization is distinct from, but complementary to, that of cannabis. While THC acts primarily via GABAergic disinhibition, nicotine acts directly on presynaptic nAChRs of VTA dopaminergic neurons, stimulating dopamine release in the striatum. Chronic use leads to desensitization of nAChRs, creating a state of cholinergic deficiency that paradoxically amplifies dopaminergic reactivity to external stimuli, which constitutes the neurobiological substrate of aberrant salience attribution. 3.3.4 The synergistic effect of co-use: a devastating dopaminergic convergence The combination of cannabis and tobacco represents a risk that exceeds the sum of its individual parts. Bello et al. (2026), in a multisite prospective study published in Nature Mental Health, used data from the North American Prodrome Longitudinal Study-2 (NAPLS-2), with 1,012 clinical high risk (CHR) participants and healthy controls (Bello et al., 2026). The results were unequivocal: heavy co-use of cannabis with light tobacco was associated with a hazard ratio of 2.93 (95% CI: 1.236.97; p = 0.015) for conversion to psychosis in survival analyses, compared to non-users. Notably, co-use was not associated with greater baseline psychiatric symptom severity, but specifically predicted conversion to psychosis, suggesting that its effect is on disease progression rather than immediate symptom expression (Bello et al., 2026). The synergistic mechanism can be understood on two levels. At the pharmacological level, THC and nicotine activate distinct dopaminergic pathways which, when combined, produce mesolimbic dopaminergic stimulation of greater magnitude than either substance alone. At the behavioral level, co-use, frequently in the form of spliffs (mixed cannabis and tobacco cigarettes), creates a pattern of more frequent use with greater cumulative exposure to THC, amplifying both acute psychotogenic effects and chronic adaptations of CB1R downregulation and nAChR desensitization. In the proposed model, co-use represents the convergence of two vectors of secondary ego erosion: cannabis-induced amotivational syndrome and subcortical dopaminergic dysregulation amplified by nicotine. The result is an accelerated collapse of the individual’s ability to maintain pragmatic contact with reality, precipitating schizophrenization in individuals with prior vulnerability, whether of a neurodevelopmental basis (ASD traits) or an affective one (BD). 13 Research, Society and Development, v. 15, n. 9, e1915951655, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51655 Table 4 - Comparative Neurochemical Profiles, Psychosis Risks, and Effects on the Secondary Self of Common Substances. Source: Authors. Table 4 - This table summarizes the neurochemical mechanisms, clinical outcomes, and reversibility associated with Cannabis (THC), Nicotine, their co-use, and Alcohol. Notably, the co-use of THC and Nicotine demonstrates a dual dopaminergic synergy, leading to a rapid collapse of the secondary self and a very high risk of psychosis (HR = 2.93) with very low reversibility compared to single-substance use. Abbreviations: VTA: Ventral Tegmental Area; CB1R: Cannabinoid Receptor Type 1; nAChRs: Nicotinic Acetylcholine Receptors; GABA: Gamma-Aminobutyric Acid; NMDA: N-Methyl-DAspartate; HR: Hazard Ratio; D₂: Dopamine D₂ Receptor. 3.4 First-rank symptoms: the evisceration of the self In classical psychopathology, Kurt Schneider defined a set of first-rank symptoms (FRS) as pathognomonic of schizophrenia, unless there was evidence of organic brain disease. These symptoms include audible thoughts, voices arguing or discussing, voices commenting on one’s actions, somatic passivity, thought insertion, thought withdrawal, thought broadcasting, and made feelings, impulses, or volitional acts. The proposed model offers a profound reinterpretation of FRS. They are not merely exotic perceptual distortions, but the direct clinical translation of the evisceration of the secondary ego. When the protective barrier that separates the internal world from external reality collapses, whether due to neurodevelopmental fragility, affective instability, or toxic erosion, the individual loses the capacity for “ipseity” (the sense of ownership of one’s own experiences). A thought is no longer experienced as my thought, but as an insertion; an impulse is no longer my impulse, but a remote control. This conceptualization is robustly supported by recent literature. Magrangeas et al. (2022), using natural language processing in 9,323 clinical records, demonstrated that specific FRS have distinct prognostic values (Magrangeas et al., 2022). Somatic passivity (OR 1.61) and thought insertion (OR 1.24) were the strongest predictors of negative outcomes. Thought broadcasting alone was not an independent predictor, suggesting that it represents an earlier stage of ego boundary dissolution, which only becomes prognostically ominous when it evolves into full loss of agency (insertion and passivity). Corlett & Fraser (2025) provided the neurobiological substrate for this phenomenological progression. By locating the primary defect of aberrant salience in the associative striatum and dorsolateral prefrontal cortex (DLPFC), circuits responsible 14 Research, Society and Development, v. 15, n. 9, e1915951655, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51655 for belief updating under uncertainty, they explained how the failure to predict the sensory consequences of self-generated actions (corollary discharge) translates into the experience of alien control. When the brain cannot correctly predict that a thought or internal speech was self-generated, it attributes this event to an external agent. López-Silva et al. (2022), in a 20-year prospective study, confirmed that thought insertion and withdrawal are strongly associated with auditory verbal hallucinations and delusions of control, forming a cohesive cluster of “ego boundary disturbances”. Crucially, they found that thought withdrawal is specifically associated with auditory verbal hallucinations, suggesting that the experience of having one’s thoughts removed creates a cognitive vacuum that is filled by hallucinatory voices. The clinical relevance of this distinction is immense. Delusions secondary to intense affective oscillations, such as the delusion of ruin in severe depression or the delusion of grandeur in mania, generally preserve the structure of the self. The patient believes they are guilty or omnipotent, but they are still themselves feeling and thinking. These are delusions with low specificity for schizophrenia and generally remit with the stabilization of the underlying mood disorder. In contrast, FRS represent the rupture of the self’s container. The presence of FRS, therefore, marks the point of no return in the schizophrenizing process: the moment when the secondary ego has been completely eviscerated. Table 5 — Predictive Value of First-Rank Symptoms (FRS). Legend: This table categorizes specific psychiatric symptoms into First-Rank Symptoms (FOS) and Non-FOS, detailing their clinical specificity, predictive value for remission, and proposed underlying mechanisms. FOS—which include "voices discussing," "voices commenting on actions," "disclosed thoughts," and "thought insertion/withdrawal"—are characterized by very high specificity and a high predictive value for remission. The proposed mechanisms for these FOS range from pure dopaminergic dysregulation and evisceration of the self to increased ego permeability and loss of agency. In contrast, Non-FOS (such as "reference delirium" and "simple persecutory delirium") exhibit low specificity and a low predictive value for remission, being primarily associated with Bipolar Disorder (BD) combined with environmental reactivity or affective instability. Abbreviations: FOS = First-Rank Symptom; BD = Bipolar Disorder. Source: Authors. 3.5 Sleep disturbances: the fifth axis of vulnerability The fifth and final axis of the interpretive matrix concerns the role of sleep disturbances in the genesis and maintenance of psychosis. Historically considered a mere epiphenomenon or secondary symptom of psychotic disorders, sleep architecture is now recognized as a fundamental pillar of neurobiological integrity and, consequently, of the secondary ego. Azargoonjahromi & Bahrampour (2025), in a comprehensive umbrella review published in Sleep Medicine, synthesized data from 20 systematic reviews and meta-analyses, confirming a strong and bidirectional association between sleep disturbances and schizophrenia. Patients with schizophrenia exhibit profound alterations in sleep architecture: reduced total sleep time, increased sleep latency, decreased sleep efficiency, and, crucially, significant reductions in slow-wave sleep and REM sleep. 15 Research, Society and Development, v. 15, n. 9, e1915951655, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51655 These alterations are not benign; they correlate directly with the worsening of hallucinations and delusions, cognitive impairment, and increased suicidality (Azargoonjahromi & Bahrampour, 2025). The impact of sleep disturbances on the clinical trajectory is devastating. Geoffroy et al. (2025), in a large-scale study of 13,913 psychiatric inpatients published in European Psychiatry, demonstrated that 81% of patients presented with chronic sleep disturbances (Geoffroy et al., 2025). More importantly, the presence of these disturbances was associated with a significantly higher number of hospitalizations (1.84 vs. 1.33), greater use of seclusion (17.6% vs. 13.3%), and physical restraint (6.6% vs. 5.3%), indicating a more severe and treatment-resistant clinical course (Geoffroy et al., 2025). The neurobiological link between sleep and psychosis involves the thalamocortical circuits responsible for sleep spindles. Torun Yazihan (2025), in a narrative review published in Applied Neuropsychology: Adult, demonstrated that sleep spindle density (11-16 Hz oscillations during NREM sleep) is significantly reduced in schizophrenia, and that this reduction is already present in the prodromal period (Torun Yazihan, 2025). Sleep spindles are essential for memory consolidation, relational learning, and synaptic plasticity. Their deficit compromises the brain’s ability to integrate new information into coherent existing schemas, which is precisely the cognitive failure that underlies aberrant salience and delusion formation. Without the restorative function of sleep spindles, the secondary ego loses its capacity to maintain narrative coherence. Furthermore, parasomnias, particularly REM sleep behavior disorder (RBD), have gained prominence as potential early markers of psychiatric vulnerability. Wang et al. (2022), in a study published in the Journal of Neurology, Neurosurgery, and Psychiatry and discussed by Wang et al. (2022) in Psychiatric Times, demonstrated that RBD, characterized by the loss of normal muscle atonia during REM sleep and the consequent enactment of dreams, can be present in up to 7% of patients with major depression, and that certain antidepressants can trigger iatrogenic RBD (Wang et al., 2022). In the context of psychosis, the intrusion of dream mentation (REM sleep) into wakefulness has been proposed as a neurobiological model for hallucinations. The fragmentation of the sleep-wake boundary parallels the fragmentation of the ego-world boundary seen in first-rank symptoms. In the proposed interpretive matrix, sleep disturbances act as a potent amplifier of vulnerability. Chronic insomnia and architectural sleep deficits erode the cognitive reserve of the secondary ego, making it more susceptible to the impact of substance use (cannabis/nicotine) and affective oscillations (BD). The clinical implication is clear: the systematic evaluation and treatment of sleep disturbances, whether through sleep hygiene, cognitive behavioral therapy for insomnia (CBT-I), or targeted pharmacological interventions, must be considered a primary strategy for neuroprotection and stabilization of the secondary ego in patients at risk for or suffering from psychosis. 3.6 Practical clinical implications The dimensional model proposed here has direct and profound implications for clinical practice: 1. Laboralization as an Existential Prosthesis: In patients with a weak secondary ego (especially those with ASD traits or amotivational syndrome), structured work acts as an external scaffolding that organizes time, demands pragmatic contact with reality, and provides predictable social feedback. Laboralization is not just occupational therapy; it is an antipsychotic intervention. 2. Targeted Substance Cessation: The co-use of cannabis and nicotine must be treated as a psychiatric emergency in individuals at high clinical risk, as it represents the most potent vector for the rapid collapse of the secondary ego. 3. Management of Expressed Emotion: Particularly in patients with ASD traits, family psychoeducation to reduce emotional over-involvement and criticism is as crucial as pharmacological treatment. 16 Research, Society and Development, v. 15, n. 9, e1915951655, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51655 4. Aggressive Sleep Management: Sleep architecture must be actively protected and restored, recognizing insomnia and parasomnias not as secondary symptoms, but as primary drivers of psychotic decompensation. 4. Limitations This integrative review has several limitations that must be acknowledged. First, the methodological heterogeneity of the included studies, ranging from neuroimaging studies to natural language processing of clinical records, precludes quantitative meta-analysis, limiting the synthesis to a narrative and interpretive approach. Second, the concept of the “secondary ego,” while phenomenologically robust and clinically useful, lacks a direct and exclusive neurobiological correlate, making its objective measurement difficult. Third, the literature search, although comprehensive, may have missed relevant studies published in languages other than English and Portuguese or indexed in databases not consulted. Finally, the proposed dimensional model, while supported by recent evidence, requires prospective validation through longitudinal studies designed specifically to test its predictive value. 5. Future Perspectives The dimensional matrix proposed in this review opens several avenues for future research. Longitudinal studies are needed to track the trajectory of the “secondary ego” from childhood to early adulthood, particularly in high-risk populations (ASD, BD, heavy substance users), using validated instruments for phenomenological assessment (e.g., EASE - Examination of Anomalous Self-Experience). Neuroimaging studies should investigate how the functional connectivity of the associative striatum and DLPFC correlates with the severity of first-rank symptoms and the degree of amotivational syndrome. Furthermore, randomized clinical trials evaluating the efficacy of specific interventions, such as early laboralization programs and intensive sleep management, in preventing conversion to psychosis in UHR individuals are essential to translate this theoretical model into concrete preventive strategies. 6. Conclusion The anatomy of schizophrenic delusion is not a static lesion, but a dynamic process of structural collapse. This integrative review demonstrates that the rigid categorical division between primary and secondary schizophrenia is insufficient to capture the complexity of psychotic disorders. Instead, the evidence supports a dimensional continuum where the central vulnerability resides in the fragility of the secondary ego, the psychic structure responsible for pragmatic mediation with reality and narrative self-coherence. The five axes investigated in this review converge precisely on this mechanism. The neurodevelopmental basis (ASD traits) provides an initially fragile or under-exercised secondary ego due to deficits in intersubjective attunement. Affective instability (BD) subjects this fragile structure to chronic stress. Psychoactive substances (cannabis and nicotine), particularly in co-use, act as potent toxic catalysts, inducing amotivational syndrome and dopaminergic dysregulation that rapidly erode the remaining cognitive reserve. Sleep disturbances amplify this vulnerability by compromising the synaptic plasticity and memory consolidation essential for narrative coherence. When the secondary ego finally collapses under the weight of these interacting factors, the neurobiological substrate, characterized by aberrant salience and dysfunction in belief-updating circuits, translates phenomenologically into the evisceration of the self. It is at this point of structural rupture that Schneider’s first-rank symptoms emerge, not merely as perceptual errors, but as the pathognomonic signature of the loss of ipseity and agency. 17 Research, Society and Development, v. 15, n. 9, e1915951655, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51655 This dimensional interpretive matrix offers a powerful tool for clinical practice. By recognizing that schizophrenization is a progressive trajectory driven by identifiable catalysts, interventions can be targeted precisely at the points of greatest vulnerability: reducing family expressed emotion, aggressively managing sleep, halting substance use, and, crucially, promoting structured laboralization as an existential prosthesis. Delusion is not the beginning of the story, but its final chapter. Recognizing this is the first step toward rewriting the outcome. References Ahrens, J., Ford, S. D., Schaefer, B. et al. (2025). Convergence of Cannabis and Psychosis on the Dopamine System. JAMA Psychiatry. 82(6):609–17. doi:10.1001/jamapsychiatry.2025.0432 Azargoonjahromi, A. & Bahrampour, Z. (2025). Sleep disturbances are associated with psychosis in schizophrenia spectrum Disorders: An umbrella review. Sleep Med. 134:106690. doi: 10.1016/j.sleep.2025.106690 Bello, B., Addington, J., Bearden, C. E., Cadenhead, K. S., Cornblatt, B. A., Mathalon, H. O. et al. (2026). Co-use of cannabis and tobacco and conversion to psychosis in clinical high-risk youth: a multisite prospective study. Nature Mental Health. 4:112-24. doi:10.1038/s44220-026-00648-y Canitano, R. & Pallagrosi, M. (2017). Autism Spectrum Disorders and Schizophrenia Spectrum Disorders: Excitation/Inhibition Imbalance and Developmental Trajectories. Front. Psychiatry. 8:69. doi: 10.3389/fpsyt.2017.00069 Corlett, P. R. & Fraser, K. M. (2025). 20 years of aberrant salience in psychosis: What have we learned? American Journal of Psychiatry. 182(9):819–29. doi:10.1176/appi.ajp.20240556 Fusar-Poli, P., Borgwardt, S., Bechdolf, A. et al. (2013). The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry. 70(1):107120. doi:10.1001/jamapsychiatry.2013.269 Geoffroy, P. A., Roure, R., Sebille, S. B., Maruani, J., Taupinard, E., Lejoyeux, M., Perozziello, A. & Mauries, S. (2025). A large-scale study of chronic sleep disorders in psychiatric inpatients: Prevalence, hospitalization burden, restraint use, and comorbidities. Eur Psychiatry. 68(1):e169. doi: 10.1192/j.eurpsy.2025.10131 Gil, A. C. (2026). Como elaborar um projeto de pesquisa. (8.ed). Editora Atlas. ISBN: 9786559777860 Henriksen, M. G., Nordgaard, J. & Jansson, L. (2017). Genetics of Schizophrenia: Overview of Methods, Findings and Limitations. Frontiers in Human Neuroscience. 11:322. doi:10.3389/fnhum.2017.00322 Howes, O. D. & Kapur, S. (2024). The dopamine hypothesis of schizophrenia: version III–the final common pathway. Schizophrenia Bulletin. 35(3):549-62. doi:10.1093/schbul/sbp006 Jablensky, A. (2021). Kraepelin’s dichotomy and the classification of psychotic disorders. Schizophrenia Bulletin. 47(5):1219-24. Jeong, S. H. & Son, J. W. (2026). The Concept of Autism in Autism Spectrum Disorder and Schizophrenia Spectrum Disorder: Historical Divergence and Phenomenological Rapprochement. Journal of the Korean Academy of Child and Adolescent Psychiatry. 37(2):82-94. doi:10.5765/jkacap.260003 Jutla, A., Foss-Feig, J. & Veenstra-VanderWeele, J. (2022). Autism spectrum disorder and schizophrenia: An updated conceptual review. Autism Research, 15(3), 384–412. doi.org/10.1002/aur.2659 Kapur, S. (2023). Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. American Journal of Psychiatry. 160(1):13-23. doi:10.1176/appi.ajp.160.1.13 Keegan, C., Brown, K. & Gaynor, K. (2025). A Systematic Review Exploring the Relationship Between Family Factors and Symptom Severity, Relapse and Social or Occupational Functioning in First-Episode Psychosis. Early Intervention in Psychiatry. 19(3):e13643. doi:10.1111/eip.13643 Krystal, J. H., D’Souza, D. C., Mathalon, D. H. et al. (2023). NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology. 206(4):515-28. doi:10.1007/s00213-003-1582-z Leucht, S;, Siafis, S., McGrath, J. J., McGorry, P., Howes, O. D., Tamminga, C. et al. (2025). Schizophrenia. Nature Reviews Disease Primers. 11:83. doi:10.1038/s41572-025-00667-6 López-Silva, P., Harrow, M., Jobe, T. H., Tufano, M., Harrow, H. & Rosen, C. (2022). Are these my thoughts?': A 20-year prospective study of thought insertion, thought withdrawal, thought broadcasting, and their relationship to auditory verbal hallucinations. Schizophr Res. 265:46-57. doi: 10.1016/j.schres.2022.07.005. Magrangeas, T. T., Kolliakou, A., Sanyal, J., Patel, R. & Stewart, R. (2022). Investigating the relationship between thought interference, somatic passivity and outcomes in patients with psychosis: a natural language processing approach using a clinical records search platform in south London. BMJ Open. 12(8):e057433. doi: 10.1136/bmjopen-2021-057433. Marano, G., Lisci, F. M., Sfratta, G., Marzo, E. M., Abate, F., Boggio, G. et al. (2025).Targeting the Roots of Psychosis: The Role of Aberrant Salience. Pediatric Reports. 17(3):63. doi:10.3390/pediatric17030063 18 Research, Society and Development, v. 15, n. 9, e1915951655, 2026 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v15i9.51655 Mu, Y., Zhang, X., Li, Y. et al. (2024). The impact of smoking on symptom improvement in first-episode schizophrenia: a prospective longitudinal study. Schizophrenia. 10:45. doi:10.1038/s41537-024-00449-1. Murrie, B., Lappin, J., Large, M. & Waters, F. (2020). Transition of Substance-Induced, Brief, and Atypical Psychoses to Schizophrenia: A Systematic Review and Meta-analysis. Schizophrenia Bulletin. 46(3):505-516. doi:10.1093/schbul/sbz102 Nusslock, R., Mittal, V. A. & Alloy, L. B. (2025). Reward Processing in Mood Disorders and Schizophrenia: A Neurodevelopmental Framework. Annu Rev Clin Psychol. 21(1):557-84. doi: 10.1146/annurev-clinpsy-080822-041621. O’Brien. K. J., Huque, Z. M., Pike, M. R., Smith, E. C., Davies, N. L. & Ellman, L. M. (2026). Synergistic pathways to psychosis: understanding developmental risk and resilience factors. Neuropsychopharmacology. 2026;51:273–292. doi:10.1038/s41386-025-02261-6 Parnas, J. & Handest, P. (2003). Phenomenology of anomalous self-experience in early schizophrenia. Compr Psychiatry. 44(2):121-34. doi: 10.1053/comp.2003.50017. Pereira, A. S., Shitsuka, D. M., Pereira, F. J. & Shitsuka, R. (2018). Metodologia do trabalho científico. Santa Maria: UAB / NTE / UFSM, 2018. ISBN: 97885-8341-204-5 Risemberg, R. I. C., Wakin, M., & Shitsuka, R. (2026). Qualitativa, quantitativa ou quali-quantitativa: Como identificar de modo rápido a abordagem de um artigo científico? E-Acadêmica, 7(2), e0172702. doi:10.52076/eacad-v7i2.702 Sass, L. A. & Parnas, J. (2003). Schizophrenia, consciousness, and the self. Schizophrenia Bulletin. 29(3):427-44. doi:10.1093/oxfordjournals.schbul.a007017 Schöttner Sieler, M., Golay, P., Vieira, S. et al. (2025). A dimensional approach to psychosis: identifying cognition, depression, and thought disorder factors in a clinical sample. Schizophr. 11, 97. doi.org/10.1038/s41537-025-00641-x Shao, Y. X., Wang, L. L., Zhou, H. Y., Yi, Z. H., Liu, S. & Yan, C. (2024). Dampened motivation in schizophrenia: evidence from a novel effort-based decisionmaking task in social scenarios. Eur Arch Psychiatry Clin Neurosci. 274(6):1447-59. doi: 10.1007/s00406-024-01761-8. Skumlien, M., Langley, C. & Sahakian, B.J. (2024). Is Cannabis Use Associated with Motivation? A Review of Recent Acute and Non-Acute Studies. Curr Behav Neurosci Rep 11, 33–43. doi.org/10.1007/s40473-023-00268-1 Stein, F. & Kircher, T. (2025). Transdiagnostic findings across major depressive disorder, bipolar disorder and schizophrenia: A qualitative review. Journal of Affective Disorders. 2025;387:119464. doi:10.1016/j.jad.2025.119464 Torun Yazıhan, N. (2025). A narrative review of clinical stages of psychosis addressing neurocognitive, sleep, and sleep spindle alterations. Appl Neuropsychol Adult. 31:1-8. doi: 10.1080/23279095.2025.2539168. Tseng, K.Y., Molla, H.M. Cannabinoid CB1 receptor-sensitive neurodevelopmental processes and trajectories. Mol Psychiatry. 30, 3792–803. doi:10.1038/s41380-025-03057-2 Uhlhaas, A. S. & Singer, W. (2020). Abnormal neural oscillations and synchrony in schizophrenia. Nature Reviews Neuroscience. 11(2):100-13. doi:10.1038/nrn2774 Wang, J., Chau, S. W. H., Lam, S. P. et al. (2022). Prevalence and correlates of REM sleep behaviour disorder in patients with major depressive disorder: a twophase study. Journal of Neurology, Neurosurgery & Psychiatry. 93:1010-7. Weinstein, A. M. (2023). A brain imaging study of dopamine receptor D2 availability in cannabis dependent users after recovery from cannabis-induced psychosis. Front Psychiatry. 14:1230760. doi: 10.3389/fpsyt.2023.1230760. 19